Serum dopamine beta hydroxylase activity and tardive dyskinesia.
A case-control study was done to test the effect of serum dopamine-beta-hydroxylase (DBH) activity on tardive dyskinesia (TD) among 85 schizophrenic outpatients treated with neuroleptics. In contrast to the results of several previous studies, we found no significant association between serum DBH activity and the occurrence or severity of TD, controlling for other TD predictors.